Emboline Announces Positive Pivotal PROTECT H2H Trial Results for Emboliner® Presented as a Late-Breaking Clinical Trial at ACC 2026

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Emboline-PROTECT-H2H

More Like This

Emboline, Inc. Completes Enrollment in U.S. Pivotal IDE Trial of the Emboliner® Embolic Protection Catheter Designed to Protect Patients from Embolic Injury During Transcatheter Aortic Valve Replacement

PR Newswire associated0

Emboline, Inc. Secures $20 Million in Growth Capital from Trinity Capital Inc. to Support Commercialization of the Emboliner® Embolic Protection System to Minimize Stroke Risk From TAVR

Emboline, Inc. Files Patent Infringement Suit Against AorticLab s.r.l. Regarding Embolic Protection Medical Device

Protembis Announces FDA Approval of its Pivotal Investigational Device Exemption (IDE) Study

Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial

Protembis Announces Completion of € 30 Million Series B Financing Round and the Addition of Keith D Dawkins MD to the Board of Directors

PR Newswire associated0

New Published Study Demonstrates Safety and Feasibility of Filterlex Medical's CAPTIS® Device in Providing Embolic Protection During TAVR

PR Newswire associated0

AorticLab S.r.l. Announces Clear Victory Before the European Unified Patent Court in Litigation Brought by Emboline, Inc.